Quality by Design I: Application of Failure Mode Effect Analysis (FMEA) and Plackett–Burman Design of Experiments in the Identification of “Main Factors” in the Formulation and Process Design Space for Roller-Compacted Ciprofloxacin Hydrochloride Immediate-Release Tablets
Abstract:As outlined in the ICH Q8(R2) guidance, identifying the critical quality attributes (CQA) is a crucial part of dosage form development; however, the number of possible formulation and processing factors that could influence the manufacturing of a pharmaceutical dosage form is enormous obviating formal study of all possible parameters and their interactions. Thus, the objective of this study is to examine how quality risk management can be used to prioritize the number of experiments needed to identify the CQA,… Show more
“…[24][25][26] The results of FMEA are represented in Table 2 in the form of risk priority numbers (RPNs) which can be used to rank the risk. It is calculated as mentioned below: …”
Section: Qtpp Of Dpm Gastroretentive Floating Tabletsmentioning
Introduction: This research focuses on development and optimization of dipyridamole (DPM) gastroretentive (GR) floating matrix tablets through risk-based approach using combination of rate controlling hydrophilic polymers. Materials and Methods: A 3 2 full factorial design was deployed to optimize ratio of polymers and polymer concentration in the formulation. Dissolution studies, Buoyancy studies, swelling index studies, kinetic modelling, drug content, and differential scanning calorimetry studies were performed to effectively assess developed gastroretentive dosage form. Estimation of related substances was also done for optimized formulations to check the stability of dosage form during shelf life. Results and Discussion: Buoyancy studies suggested that concentration of PanExcea™ GR polymer should be at least 25% w/w or more to get better floating and swelling capabilities if used alone as rate controlling polymer. Selection of optimum batches was done using constraintbased graphical optimization technique. The optimum batches exhibited desired extended drug dissolution profile, minimal floating lag time, and total floating time of >12 h. Thermal characterization studies also preclude any drug polymer interaction and change in polymorphic form of drug during manufacturing process. Stability studies indicated optimized formulations are stable under selected packaging configurations. Conclusion: The present research exemplifies successful application of quality by design approach in designing gastroretentive dosage form of DPM. From the present study, it can be concluded that selection of appropriate ratio and concentration of hydrophilic polymers play a pivotal role in matrix integrity, buoyancy, swelling potential as well as drug release profile of GRDDS.
“…[24][25][26] The results of FMEA are represented in Table 2 in the form of risk priority numbers (RPNs) which can be used to rank the risk. It is calculated as mentioned below: …”
Section: Qtpp Of Dpm Gastroretentive Floating Tabletsmentioning
Introduction: This research focuses on development and optimization of dipyridamole (DPM) gastroretentive (GR) floating matrix tablets through risk-based approach using combination of rate controlling hydrophilic polymers. Materials and Methods: A 3 2 full factorial design was deployed to optimize ratio of polymers and polymer concentration in the formulation. Dissolution studies, Buoyancy studies, swelling index studies, kinetic modelling, drug content, and differential scanning calorimetry studies were performed to effectively assess developed gastroretentive dosage form. Estimation of related substances was also done for optimized formulations to check the stability of dosage form during shelf life. Results and Discussion: Buoyancy studies suggested that concentration of PanExcea™ GR polymer should be at least 25% w/w or more to get better floating and swelling capabilities if used alone as rate controlling polymer. Selection of optimum batches was done using constraintbased graphical optimization technique. The optimum batches exhibited desired extended drug dissolution profile, minimal floating lag time, and total floating time of >12 h. Thermal characterization studies also preclude any drug polymer interaction and change in polymorphic form of drug during manufacturing process. Stability studies indicated optimized formulations are stable under selected packaging configurations. Conclusion: The present research exemplifies successful application of quality by design approach in designing gastroretentive dosage form of DPM. From the present study, it can be concluded that selection of appropriate ratio and concentration of hydrophilic polymers play a pivotal role in matrix integrity, buoyancy, swelling potential as well as drug release profile of GRDDS.
“…The ease at which a failure mode can be detected defines the parameter D. The more measurable a failure mode is, the lesser risk process holds. Multiplying these values would result in the risk priority number (RPN) [15].…”
The Food and Drug Administration (FDA) first approved PEGylated product in 1990, since then PEGylation, as a modification procedure for enhancing biomedical efficiency and physicochemical properties of therapeutic proteins has been extensively used. Recombinant proteins are prone to rapid degradation due to proteolysis or may have a brief circulating half-life due to low renal filtration. These limitations can be overcome by PEGylation, where polyethylene glycol chains are linked to peptides and protein molecules. The quality by design (QbD) paradigm helps to develop a process design spaces which describes the interactions and multidimensional effects of method variables on critical quality attributes of therapeutic proteins. The complexities involved in manufacturing processes have led to the development of strategies to establish a design space, ensuring reliable and reproducible outcomes. QbD approach in process optimization allows simultaneous screening of process variables, thus reducing the number of tests conducted as compared to the traditional approach based on a trial and error method. An approach to QbD using the design of experiments (DOE) has been used to establish a design space for PEGylation of recombinant proteins. The aim of this paper is to provide a systematic approach for implementing quality by design for development of a protein PEGylation process.
“…The mixing, roller compaction, and tableting stages are shown with the process parameters for each stage listed below and the output parameters shown above the stages in italics study, two separate DOEs were performed to identify the design space: study 1, a small-scale study with a 0.5 kg batch size that examined only processing variables, and study 2, a larger-scale study with a 3.6 or 1.0 kg batch size that examined both processing and formulation variables and their interactions. The base formulation and process conditions, which studies 1 and 2 are built around, are given in Table I, and are based upon our previous study (4). The numerical values for the DOE conditions and results for studies 1 and 2 are given in an Excel® spreadsheet that is provided as supplemental spreadsheet for this manuscript; in this spreadsheet, formulation F5 is the base formulation of Table I.…”
Section: Doe Descriptionmentioning
confidence: 99%
“…The Carr Index (CI) was calculated as follows: Granule size was measured by laser diffraction using the Malvern Mastersizer (Malvern Inc., Worcestershire, UK) with a sample size of 5 g operated at an air pressure of 20 psi and a feed rate setting of 2.5. The average mean particle size was D [4,3] and the span, (D 90 -D 10 )/D 50 ; the reported values for these parameters are the average of three replicates.…”
Section: Granule Evaluationmentioning
confidence: 99%
“…The goal of this paper is to continue our illustration of how qualitative and quantitative risk tools can be used in quality-by-design approaches to rationally guide the balance between too many and too few experiments during product development, and to target resources to the factors that can have the greatest impact on patient health (4). This study extends the previous qualitative study and illustrates the use of quantitative Monte Carlo techniques to define the design space and quantitate the uncertainty associated with the design space boundaries.…”
Abstract. Qualitative risk assessment methods are often used as the first step to determining design space boundaries; however, quantitative assessments of risk with respect to the design space, i.e., calculating the probability of failure for a given severity, are needed to fully characterize design space boundaries. Quantitative risk assessment methods in design and operational spaces are a significant aid to evaluating proposed design space boundaries. The goal of this paper is to demonstrate a relatively simple strategy for design space definition using a simplified Bayesian Monte Carlo simulation. This paper builds on a previous paper that used failure mode and effects analysis (FMEA) qualitative risk assessment and Plackett-Burman design of experiments to identity the critical quality attributes. The results show that the sequential use of qualitative and quantitative risk assessments can focus the design of experiments on a reduced set of critical material and process parameters that determine a robust design space under conditions of limited laboratory experimentation. This approach provides a strategy by which the degree of risk associated with each known parameter can be calculated and allocates resources in a manner that manages risk to an acceptable level.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.